Anemoside B4 improves cardiac function after myocardial infarction by regulating HTR2A/ERK pathway
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115394 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Mei Lv und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Medicine Department, Yantaishan Hospital, Yantai, Shandong 264000, China. Hauptthemen laut MEDLINE: Myocardial Infarction, Myocytes, Cardiac, Saponins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Assessing the role of anemoside B4 (B4) in myocardial infarction (MI) and the regulatory mechanism was the purpose of this study. METHODS: We established MI rat model through ligation of the left anterior descending coronary artery and cardiomyocyte injury model through H2O2 stimulation. The effects of B4 on cardiac function in MI rat model were assessed utilizing echocardiography, histological staining, and western blot. In vitro, CCK-8, flow cytometer, and ELISA were utilized for assessing B4's effects on cardiomyocyte viability, apoptosis, inflammatory response. The network pharmacology was applied for exploring B4's mechanism in MI. RESULTS: In vivo, B4 alleviated myocardial injury, as evidenced by improving cardiac function parameters, reduced collagen synthesis and deposition, preserved cardiac structure, and decreased apoptosis, inflammation response, and oxidative stress. In vitro, B4 enhanced cell viability and inhibited oxidative stress, apoptosis, and inflammation response. Mechanistically, based on molecular docking, B4-HTR2A complex was found to have a good binding activity. Furthermore, B4 reduced HTR2A and p-ERK/ERK protein expression in MI rat model and cardiomyocyte injury model. More importantly, the effects of B4 on cardiomyocyte viability, oxidative stress, apoptosis, and inflammation were reversed by HTR2A overexpression. HTR2A knockdown alleviated H2O2-induced oxidative stress, apoptosis, and inflammation. CONCLUSION: B4 protected cardiomyocytes and alleviated cardiac dysfunction, oxidative stress, inflammation, and apoptosis, which were partly mediated by inhibiting HTR2A/ERK pathway. B4 may be a promising therapeutic drug for MI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Medicine Department, Yantaishan Hospital, Yantai, Shandong 264000, China.
- Department of Cardiology, Yantaishan Hospital, Yantai, Shandong 264000, China.
- Preventive medicine, Shandong University, Jinan, Shandong 250000, China.
- Department of Cardiology, Yantaishan Hospital, Yantai, Shandong 264000, China. Electronic address: 13356998338@189.cn.
Zitieren
APA
Lv, M., Sun, Q., Yu, Y., & Yu, D. (2025). Anemoside B4 improves cardiac function after myocardial infarction by regulating HTR2A/ERK pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115394
Vancouver
Lv M, Sun Q, Yu Y, Yu D. Anemoside B4 improves cardiac function after myocardial infarction by regulating HTR2A/ERK pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115394
BibTeX
@article{Lv2025,
author = {Lv, Mei and Sun, Qing and Yu, Yilin and Yu, Dawei},
title = {Anemoside B4 improves cardiac function after myocardial infarction by regulating HTR2A/ERK pathway},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115394}
}
EUVIMED